PMCF Study of MPS-Flex® Knee System in TKA

July 22, 2024 updated by: Zimmer Biomet

A Multi-Centre Post Market Clinical Follow-Up Study of MPS-Flex® Total Knee Joint Prostheses in Total Knee Arthroplasty

The objective of this study is to obtain implant survivorship and clinical outcomes data for the commercially available MPS-Flex® Total Knee Joint Prostheses used in primary total knee arthroplasty (TKA).

Study Overview

Status

Suspended

Detailed Description

This is a retrospective and prospective, multi-centre, post-market clinical follow-up study involving orthopedic surgeons skilled in TKA and experienced implanting the devices included in this study. Patient demographic and operative information will be collected retrospectively. Postoperative clinical outcome, radiographic assessment and adverse events will be collected prospectively starting from the first year of postoperative follow up visit.

All study subjects have undergone routine preoperative clinical evaluations prior to their THA, and implanted MPS-Flex® Total Knee Joint Prostheses in accordance to indications and intended use, and appropriate surgical technique(s) will be invited to participate in the study at their first year of postoperative follow up visit, and sign ICF.

Study Type

Observational

Enrollment (Actual)

250

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Hebei
      • Handan, Hebei, China
        • Jizhong Erengy Fengfeng Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population for primary statistical analysis will consist of patients who have already underwent their surgery with MPS-Flex® Total Knee Joint Prostheses for their primary TKA and satisfy eligibility criteria outlined in this section. In order to avoid potential selection bias, each investigator will offer study participation to each consecutive eligible patient presenting as a candidate for primary TKA using the MPS-Flex® Total Knee Joint Prostheses.

Description

Inclusion Criteria:

A patient must meet the following criteria to be eligible for participation:

  • Age 18 to 75 years old, inclusive.
  • Had a primary unilateral or bilateral (simultaneous or staged)TKA based on physical exam and medical history, including diagnosis of severe knee pain and disability due to at least one of the following:

    1. Rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis.
    2. Collagen disorders and/or avascular necrosis of the femoral condyle.
    3. Post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy.
    4. Moderate valgus, varus, or flexion deformities.
  • Had received MPS-Flex® Total Knee Joint Prostheses per the approved indications for use for the TKA.
  • Willing and able to provide written informed consent by signing and dating the EC approved informed consent form.
  • Willing and able to complete scheduled study procedures and follow-up evaluations.

Exclusion Criteria:

A patient must not meet the following criteria to be eligible for participation:

  • The patient is:

    1. A prisoner
    2. Mentally incompetent or unable to understand what participation in the study entails
    3. A known alcohol or drug abuser
    4. Anticipated to be non-compliant
  • Meet any of the following contraindications of the product.

    1. Had previous infection in the operative knee joint, and/or has systemic inflection that could affect prosthesis
    2. Insufficient bone stock of tibia or tibia surface
    3. Skeleton immaturity
    4. Neuropathic arthropathy
    5. Osteoporosis, muscle structure or neuromuscular lesions which affects lower limb function
    6. The affected joint occurs fusion in the satisfactory functional position and form stable,
    7. A history of rheumatoid arthritis with skin ulcers or recurrent skin damage
  • Has a diagnosed systemic disease that could affect his/her safety or the study outcome.
  • Known sensitivity or allergic reaction to one or more of the implanted materials.
  • Known local bone tumors and/or cysts in the operative knee
  • Known to be pregnant
  • Body Mass Index (BMI) ≥ 40

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
MPS-Flex Total Knee Joint Prostheses
Patients who have received MPS-Flex Total Knee Joint Prostheses for their primary TKA and meet the Patient Selection Criteria outlined in the study protocol.
Patients who have received MPS-Flex Total Knee Joint Prostheses for their primary TKA and meet the Patient Selection Criteria outlined in the study protocol.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Implant survivorship based on revision
Time Frame: 10 years
Implant survival will be summarized using a Kaplan-Meier method.
10 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of life based on EQ-5D questionnaire
Time Frame: 10 years
EQ-5D is a standardized measure of health-related quality of life states consisting of 5 dimensions, namely mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D-5L version was used in the study. Each dimension has 5 responses recording 5 levels of severity (no problems/slight problems/moderate problems/severe problems or extreme problems). The responses to the EQ-5D dimensions are used to obtain a single EQ-5D index value where 1 represents full health and 0 represents death. The questionnaire also includes a vertical, visual analogue scale (EQ VAS) for the respondents to record their self-rated health where the 2 extreme ends of the scale are labelled as 'Best imaginable health state' and 'Worst imaginable health state' respectively.
10 years
Safety assessment
Time Frame: 10 years
Summarize the category, incidence and frequency of adverse events
10 years
Functional outcome based on Knee Society Score
Time Frame: 10 years
The Knee Society Scoring System combines an objective physician-derived component with a subjective patient-derived component that evaluates pain relief, functional abilities, satisfaction, and fulfillment of expectations. It consists of four subscales: (1) Objective Knee Score (seven items; 100 points), (2) Satisfaction Score (five items; 40 points), (3) Expectation Score (three items; 15 points), and (4) Functional Activity Score (19 items; 100 points).
10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Zhenzhong Guo, Professor, Jizhong Erengy Fengfeng Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 25, 2021

Primary Completion (Estimated)

August 31, 2024

Study Completion (Estimated)

December 31, 2024

Study Registration Dates

First Submitted

June 9, 2020

First Submitted That Met QC Criteria

June 9, 2020

First Posted (Actual)

June 11, 2020

Study Record Updates

Last Update Posted (Actual)

July 24, 2024

Last Update Submitted That Met QC Criteria

July 22, 2024

Last Verified

July 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • CSA2019-11K

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Total Knee Arthroplasty

Clinical Trials on MPS-Flex Total Knee Joint Prostheses

Subscribe